Last Updated: May 11, 2026

Claims for Patent: 12,053,463

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,053,463

Title:	Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Abstract:	The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
Inventor(s):	George P. Luke, Pratik SHETH
Assignee:	Forma Therapeutics Inc
Application Number:	US18/215,727
Patent Claims:	1. A solid form of Compound 1: characterized by an X-ray Powder Diffraction (XRPD) pattern with a peak at angle (2 theta±0.2) of 6.3. 2. The solid form of claim 1, wherein the XRPD pattern further comprises a peak at angle (2 theta±0.2) of 5.7. 3. The solid form of claim 1 characterized by a differential scanning calorimetry (DSC) thermogram with an endothermic event observed at about 256.6° C. 4. An oral unit dosage form comprising, a solid form of (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, wherein the solid form is characterized by an X-ray Powder Diffraction (XRPD) pattern with a peak at angle (2 theta±0.2) of 6.3, and one or more excipients selected from the group consisting of a filler, a disintegrant, a lubricant, and a glidant. 5. The oral unit dosage form of claim 4, comprising a total of about 50-150 mg of the ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile. 6. The oral unit dosage form of claim 4, comprising a total of about 150 mg of the ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile. 7. The oral unit dosage form of claim 4, comprising a filler wherein the filler comprises microcrystalline cellulose. 8. The oral unit dosage form of claim 4, comprising a disintegrant, wherein the disintegrant comprises croscarmellose sodium. 9. The oral dosage unit of claim 4, comprising a glidant, wherein the glidant comprises colloidal silicon dioxide. 10. The oral dosage unit of claim 4, further comprising a lubricant. 11. The oral dosage unit of claim 10, wherein the lubricant comprises magnesium stearate. 12. The oral dosage unit of claim 4, wherein the (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile is about 33 percent by weight of the oral dosage unit. 13. The oral dosage unit of claim 10, wherein the (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, the filler, the disintegrant and the lubricant are present in a relative weight ratio of about 33:61:5:1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.